Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arbaclofen extended release - RVL Pharmaceuticals

Drug Profile

Arbaclofen extended release - RVL Pharmaceuticals

Alternative Names: Arbaclofen extended release tablets (AERT) - RVL Pharmaceuticals; Ontinua ER; OS-440

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Osmotica Pharmaceutical
  • Developer RVL Pharmaceuticals
  • Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Muscle spasticity
  • No development reported Opioid-related disorders

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Opioid-related-disorders in USA (PO, Tablet)
  • 28 Feb 2022 RVL Pharmaceuticals has patent protection for Arbaclofen extended release in USA
  • 19 Jan 2022 Osmotica Pharmaceuticals is now called RVL Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top